Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.
Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/.
About the Benzinga Global Small Cap Conference
The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.
For more information and/or to register for the conference please visit: https://www.benzinga.com/events/small-cap/december-2021-global/.
We look forward to seeing you there.
For further information:
Lexaria Bioscience Corp.
George Jurcic
250-765-6424, ext 202
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.lexariabioscience.com
| Last Trade: | US$1.37 |
| Daily Change: | -0.04 -2.50 |
| Daily Volume: | 101,065 |
| Market Cap: | US$23.960M |
December 19, 2024 December 17, 2024 December 09, 2024 November 20, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
